摘要:目的 探討丹紅注射液聯(lián)合甲鈷胺治療糖尿病周圍神經(jīng)病變的療效。方法 將126例入院患者隨機(jī)分為2組,在常規(guī)治療基礎(chǔ)上,治療組予丹紅注射液聯(lián)合甲鈷胺肌肉注射治療,對照組單用甲鈷胺肌肉注射治療,療程均為1個月,觀察治療后癥狀改善情況,測定脛神經(jīng)、腓總神經(jīng)運(yùn)動神經(jīng)傳導(dǎo)速度,肥腸神經(jīng)、腓淺神經(jīng)感覺神經(jīng)傳導(dǎo)速度。結(jié)果 治療組臨床癥狀、神經(jīng)功能評分、神經(jīng)傳導(dǎo)速度的改善情況均明顯優(yōu)于對照組(P<0.05)。結(jié)論 丹紅注射液聯(lián)合甲鈷胺治療糖尿病周圍神經(jīng)病變安全有效,優(yōu)于單獨(dú)應(yīng)用甲鈷胺。
關(guān)鍵詞:糖尿病周圍神經(jīng)病變;丹紅注射液;甲鈷胺
Observation of Danhong Injection Combined Methylcobalamin in Treatment of Diabetic Peripheral Neuropathy
HU Yi-qiang
(92487th Military Hospital,Lingshui 572400,Hainan,China)
Abstract:Objective Danhong injection of methylcobalamin on diabetic peripheral neuropathy. Methods 126 cases of hospitalized patients were randomly divided into 2 groups on the basis of conventional therapy, the treatment group to Danhong injection intramuscular methylcobalamin treatment, control group injected alone methylcobalamin treatment, a course of 1 month After treatment, improvement of symptoms, determination of tibial nerve, common peroneal nerve motor nerve conduction velocity, Intestines nerve, superficial peroneal nerve sensory nerve conduction velocity. Results Clinical symptoms, neurological score, the improvement in nerve conduction velocity was significantly better than the control group (P<0.05). Conclusion Danhong injection of methylcobalamin on diabetic peripheral neuropathy is safe and effective, than alone Methylcobalamin.
Key words:Diabetic peripheral neuropathy; Danhong injection; Methylcobalamin
糖尿病周圍神經(jīng)病變是糖尿病最常見的慢性并發(fā)癥之一,發(fā)病率高達(dá)805~90%,位居其他并發(fā)癥之首,是DM患者致殘的主要因素,嚴(yán)重影響了患者的生活質(zhì)量。其發(fā)病機(jī)制尚未完全闡明。但是,代謝障礙及血管損害在糖尿病周圍神經(jīng)病變的產(chǎn)生過程中起了重要作用。單用西藥療效不佳。筆者2008年5月~2010年3月應(yīng)用丹紅注射液聯(lián)合彌可保治療以及單用彌可保治療糖尿病周圍神經(jīng)病變患者126例,獲得較好療效,現(xiàn)報(bào)告如下。
2 結(jié)果
2.1治療前后空腹血糖、餐后2h血糖比較 治療前治療組與對照組相比空腹血糖、餐后2h血糖無統(tǒng)計(jì)學(xué)差異。治療組治療前后相比空腹血糖、餐后2h血糖無統(tǒng)計(jì)學(xué)差異。治療后治療組與對照組相比空腹血糖、餐后2h血糖無統(tǒng)計(jì)學(xué)差異(見表1)。
2.2治療前后臨床癥狀與體征比較 治療組治療后與治療前相比手足麻木、肢體疼痛、局部冷感、燒灼感改善率有統(tǒng)計(jì)學(xué)差異(見表2)。……